Research Fellowship
National Cancer Institute/NIH (2013)
Medical School
University of Michigan Medical School (2014)
Santa Clara Valley Medical Center (2015), Transitional Year
University of North Carolina Hospitals (2019), Radiation Oncology

Research Interest

  • Combination strategies of radiation with systemic therapy including targeted therapy and immunotherapy
  • Development of biomarkers to help assess response to therapy, guide treatment intensification or de-intensification, and detect early recurrence
  • Investigation of patient-reported outcomes and toxicities related to radiation therapy


Featured Publications LegendFeatured Publications

Incidence of, and risk factors for, mandibular osteoradionecrosis in patients with oral cavity and oropharynx cancers.
Moon DH, Moon SH, Wang K, Weissler MC, Hackman TG, Zanation AM, Thorp BD, Patel SN, Zevallos JP, Marks LB, Chera BS, Oral Oncol. 2017 09 72 98-103
Patterns of Care of Node-Positive Prostate Cancer Patients Across the United States: A National Cancer Data Base Analysis.
Moon DH, Basak RS, Chen RC, Clin Genitourin Cancer 2017 Aug
Comparison of Patient Report and Medical Records of Comorbidities: Results From a Population-Based Cohort of Patients With Prostate Cancer.
Ye F, Moon DH, Carpenter WR, Reeve BB, Usinger DS, Green RL, Spearman K, Sheets NC, Pearlstein KA, Lucero AR, Waddle MR, Godley PA, Chen RC, JAMA Oncol 2017 Aug 3 8 1035-1042
What is the best way to radiate the prostate in 2016?
Moon DH, Efstathiou JA, Chen RC, Urol. Oncol. 2017 02 35 2 59-68
Long-term quality of life after swallowing and salivary-sparing chemo-intensity modulated radiation therapy in survivors of human papillomavirus-related oropharyngeal cancer.
Vainshtein JM, Moon DH, Feng FY, Chepeha DB, Eisbruch A, Stenmark MH, Int. J. Radiat. Oncol. Biol. Phys. 2015 Apr 91 5 925-33
Radiation-induced intradural malignant peripheral nerve sheath tumor of the cauda equina with diffuse leptomeningeal metastasis.
Lau D, Moon DH, Park P, Hervey-Jumper S, McKeever PE, Orringer DA, J Neurosurg Spine 2014 Nov 21 5 719-26
Targeted radiosensitization with PARP1 inhibition: optimization of therapy and identification of biomarkers of response in breast cancer.
Feng FY, Speers C, Liu M, Jackson WC, Moon D, Rinkinen J, Wilder-Romans K, Jagsi R, Pierce LJ Breast Cancer Res. Treat. 2014 Aug 147 1 81-94
Beyond Breast and Ovarian Cancers: PARP Inhibitors for BRCA Mutation-Associated and BRCA-Like Solid Tumors.
O'Sullivan CC, Moon DH, Kohn EC, Lee JM, Front Oncol 2014 4 42
Deleterious BRCA1/2 mutation is an independent risk factor for carboplatin hypersensitivity reactions.
Moon DH, Lee JM, Noonan AM, Annunziata CM, Minasian L, Houston N, Hays JL, Kohn EC, Br. J. Cancer 2013 Aug 109 4 1072-8


Featured Books Legend Featured Books

Ovarian Cancer. In The Bethesda Handbook of Clinical Oncology

Lee J-M, Buckley de Meritens A, Moon DH, Kohn EC. (2014). Philadelphia, Lippincott Williams & Wilkins

Glioblastoma. In Hypofractionated and Stereotactic Radiation Therapy: A Practical Guide

Moon DH, Zagar TM. (2018). Springer International Publishing

Secondary Malignant (Metastases). In Hypofractionated and Stereotactic Radiation Therapy: A Practical Guide

Moon DH, Zagar TM. (2018). Springer International Publishing

Honors & Awards

  • Pope Clinical Trainee Award, University of North Carolina
  • RSNA Roentgen Resident/Fellow Research Award
  • Society for Translational Oncology Rising Star in Oncology
  • Medical Research Scholars Program, National Institutes of Health
  • J. Griswold and Margery H. Ruth Scholarship, University of Michigan Medical School

Professional Associations/Affiliations

  • American Society for Radiation Oncology (ASTRO)
  • American Society of Clinical Oncology (ASCO)